Astria Therapeutics Inc. (ATXS), a biopharmaceutical company developing life-changing therapies for rare and niche allergic and immunological diseases, has a clinical trial catalyst to watch this quarter.
The company's lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein for the preventative treatment of Hereditary Angioedema (HAE), a rare genetic disorder characterized by severe, unpredictable, sometimes life-threatening swelling.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com